Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol) by lowering uric acid levels in the blood.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Febuxostat

Criteria

Inclusion Criteria:

• Age > 21 years

• Gout

• Hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women).

Exclusion Criteria:

• Current treatment with insulin, azathioprine, mercaptopurine, or theophylline.

• Treatment with febuxostat, allopurinol or other uricosuric agents (including losartan, probenecid) within the past year

• Uncontrolled hypertension (clinic systolic blood pressure > 160 mmHg or diastolic blood pressure > 90 mmHg within the past 6 months)

• Uncontrolled diabetes mellitus (HbA1c > 7%)

• estimated GFR < 60 ml/min by MDRD

• Elevated liver function tests (AST or ALT greater than 3 times the upper limit of normal)

• Pregnancy